Search
Vardenafil
go.drugbank.com/drugs/DB00862Approved[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.
Amisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigational[L32759] It is marketed under the brand name Barhemsys.
Synonyms: 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamideBesilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801ApprovedPariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawn[A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.
Glutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalIt conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Synonyms: N-(N-gamma-L-Glutamyl-L-cysteinyl)glycineSulfacytine
go.drugbank.com/drugs/DB01298ApprovedAlthough these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. … Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally.
Synonyms: 1-ethyl N4-sulfanilylcytosin, 1-ethyl-N-sulfanilylcytosineBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalLymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. … This demonstrates meaningful progress in treatment for patients affected by this disease.[L1739]